Skip to main content
NCBI home page
California Medicine logoLink to California Medicine
. 1969 Mar;110(3):231–243.

Current Concepts of Hyperuricemia and Gout

James R Klinenberg
PMCID: PMC1503450  PMID: 5773483

Abstract

Recent studies have confirmed that gout is an inborn error of metabolism. It has now become evident that the hyperuricemia associated with gout might occur either due to overproduction of uric acid, underexcretion of uric acid or a combination of these processes. Furthermore, patients with excessive purine synthesis may have a specific enzyme defect resulting in altered feedback inhibition of purine synthesis. A neurological disease manifest by mental retardation, choreo-athetosis, aggressive behavior, lip-biting and self-mutilation and associated with decidedly increased purine biosynthesis serves as a prototype of this kind of disorder. Other defects in regulation of purine biosynthesis have been postulated but their existence not yet confirmed.

It has been demonstrated that urate crystals which are deposited from hyperuricemic body fluids set up an acute inflammatory reaction by means of a variety of chemical mediators. Thus, acute gouty arthritis is now recognized as an example of “crystal induced” synovitis.

The treatment of gout consists of (1) the control of acute gouty attacks, and (2) the maintenance of normal serum uric acid concentrations. This latter may be achieved either with uricosuric drugs or with xanthine oxidase inhibition. With these principles in mind, it is now possible to avoid many of the severe crippling effects of gout and to restore the vast majority of gouty patients to useful and productive lives.

Full text

PDF
231

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AYVAZIAN J. H., AYVAZIAN L. F. A study of the hyperuricemia induced by hydrochlorothiazide and acetazolamide separately and in combination. J Clin Invest. 1961 Nov;40:1961–1966. doi: 10.1172/JCI104421. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Alepa F. P., Howell R. R., Klinenberg J. R., Seegmiller J. E. Relationships between glycogen storage disease and tophaceous gout. Am J Med. 1967 Jan;42(1):58–66. doi: 10.1016/0002-9343(67)90006-x. [DOI] [PubMed] [Google Scholar]
  3. Alvsaker J. O. Genetic studies in primary gout. Investigations on the plasma levels of the urate-binding alpha 1-alpha 2-globulin in individuals from two gouty kindreds. J Clin Invest. 1968 Jun;47(6):1254–1261. doi: 10.1172/JCI105817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Alvsaker J. O. Uric acid in human plasma. 3. Investigations on the interaction between the urate ion and human albumin. Scand J Clin Lab Invest. 1965;17(5):467–475. [PubMed] [Google Scholar]
  5. Alvsaker J. O. Uric acid in human plasma. V. Isolation and identification of plasma proteins interacting with urate. Scand J Clin Lab Invest. 1966;18(2):227–239. doi: 10.3109/00365516609051819. [DOI] [PubMed] [Google Scholar]
  6. Brockman R. W. Resistance to purine antagonists in experimental leukemia systems. Cancer Res. 1965 Oct;25(9):1596–1605. [PubMed] [Google Scholar]
  7. Castelnuovo-Tedesco P. Psychiatric observations on attacks of gout in a patient with ulcerative colitis. Report of a case. Psychosom Med. 1966 Nov-Dec;28(6):781–788. doi: 10.1097/00006842-196611000-00001. [DOI] [PubMed] [Google Scholar]
  8. DAVIDSON J. D., WINTER T. S. PURINE NUCLEOTIDE PYROPHOSPHORYLASES IN 6-MERCAPTOPURINE-SENSITIVE AND -RESISTANT HUMAN LEUKEMIAS. Cancer Res. 1964 Feb;24:261–267. [PubMed] [Google Scholar]
  9. EISEN A. Z., SEEGMILLER J. E. Uric acid metabolism in psoriasis. J Clin Invest. 1961 Aug;40:1486–1494. doi: 10.1172/JCI104379. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. ENGELMAN K., WATTS R. W., KLINENBERG J. R., SJOERDSMA A., SEEGMILLER J. E. CLINICAL, PHYSIOLOGICAL AND BIOCHEMICAL STUDIES OF A PATIENT WITH XANTHINURIA AND PHEOCHROMOCYTOMA. Am J Med. 1964 Dec;37:839–861. doi: 10.1016/0002-9343(64)90128-7. [DOI] [PubMed] [Google Scholar]
  11. FREUDWEILER M. EXPERIMENTAL INVESTIGATIONS INTO THE ORIGIN OF GOUTY TOPHI. Arthritis Rheum. 1965 Apr;8:267–288. doi: 10.1002/art.1780080210. [DOI] [PubMed] [Google Scholar]
  12. GOLDFINGER S., KLINENBERG E., Jr, SEEGMILLER J. E. RENAL RETENTION OF URIC ACID INDUCED BY INFUSION OF BETA-HYDROXYBUTYRATE AND ACETOACETATE. N Engl J Med. 1965 Feb 18;272:351–355. doi: 10.1056/NEJM196502182720705. [DOI] [PubMed] [Google Scholar]
  13. GOLDFINGER S., KLINENBERG J. R., SEEGMILLER J. E. THE RENAL EXCRETION OF OXYPURINES. J Clin Invest. 1965 Apr;44:623–628. doi: 10.1172/JCI105175. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. GRAYZEL A. I., SEEGMILLER J. E., LOVE E. Suppression of uric acid synthesis in the gouty human by the use of 6-diazo-5-oxo-L-norleucine. J Clin Invest. 1960 Mar;39:447–454. doi: 10.1172/JCI104057. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. GUTMAN A. B., YU T. F., BERGER L. Tubular secretion of urate in man. J Clin Invest. 1959 Oct;38:1778–1781. doi: 10.1172/JCI103956. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. GUTMAN A. B., YU T. F. Renal function in gout; with a commentary on the renal regulation of urate excretion, and the role of the kidney in the pathogenesis of gout. Am J Med. 1957 Oct;23(4):600–622. doi: 10.1016/0002-9343(57)90231-0. [DOI] [PubMed] [Google Scholar]
  17. Goldfinger S. E., Howell R. R., Seegmiller J. E. Suppression of metabolic accompaniments of phagocytosis by colchicine. Arthritis Rheum. 1965 Dec;8(6):1112–1122. doi: 10.1002/art.1780080610. [DOI] [PubMed] [Google Scholar]
  18. Gutman A. B. Treatment of primary gout: the present status. Arthritis Rheum. 1965 Oct;8(5):911–920. doi: 10.1002/art.1780080502. [DOI] [PubMed] [Google Scholar]
  19. Gutman A. B. Uricosuric drugs, with special reference to probenecid and sulfinpyrazone. Adv Pharmacol. 1966;4:91–142. doi: 10.1016/s1054-3589(08)60098-8. [DOI] [PubMed] [Google Scholar]
  20. HENDERSON J. F. Feedback inhibition of purine biosynthesis in ascites tumor cells. J Biol Chem. 1962 Aug;237:2631–2635. [PubMed] [Google Scholar]
  21. HOEFNAGEL D., ANDREW E. D., MIREAULT N. G., BERNDT W. O. HEREDITARY CHOREOATHETOSIS, SELF-MUTILATION AND HYPERURICEMIA IN YOUNG MALES. N Engl J Med. 1965 Jul 15;273:130–135. doi: 10.1056/NEJM196507152730303. [DOI] [PubMed] [Google Scholar]
  22. HOWELL R. R., EANES E. D., SEEGMILLER J. E. X-ray diffraction studies of the tophaceous deposits in gout. Arthritis Rheum. 1963 Apr;6:97–103. doi: 10.1002/art.1780060202. [DOI] [PubMed] [Google Scholar]
  23. Henderson J. F., Rosenbloom F. M., Kelley W. N., Seegmiller J. E. Variations in purine metabolism of cultured skin fibroblasts from patients with gout. J Clin Invest. 1968 Jul;47(7):1511–1516. doi: 10.1172/JCI105844. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. KLINENBERG J. R., GOLDFINGER S. E., SEEGMILLER J. E. THE EFFECTIVENESS OF THE XANTHINE OXIDASE INHIBITOR ALLOPURINOL IN THE TREATMENT OF GOUT. Ann Intern Med. 1965 Apr;62:639–647. doi: 10.7326/0003-4819-62-4-639. [DOI] [PubMed] [Google Scholar]
  25. KUZELL W. C., SCHAFFARZICK R. W., NAUGLER W. E., GAUDIN G., MANKLE E. A., BROWN B. Phenylbutazone (butazolidin) in gout. Am J Med. 1954 Feb;16(2):212–217. doi: 10.1016/0002-9343(54)90336-8. [DOI] [PubMed] [Google Scholar]
  26. Kellermeyer R. W. Activation of Hageman factor by sodium urate crystals. Arthritis Rheum. 1965 Oct;8(5):741–743. doi: 10.1002/art.1780080434. [DOI] [PubMed] [Google Scholar]
  27. Kelley W. N., Rosenbloom F. M., Henderson J. F., Seegmiller J. E. A specific enzyme defect in gout associated with overproduction of uric acid. Proc Natl Acad Sci U S A. 1967 Jun;57(6):1735–1739. doi: 10.1073/pnas.57.6.1735. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Kelley W. N., Rosenbloom F. M., Miller J., Seegmiller J. E. An enzymatic basis for variation in response to allopurinol. Hypoxanthine-guanine phosphoribosyltransferase deficiency. N Engl J Med. 1968 Feb 8;278(6):287–293. doi: 10.1056/NEJM196802082780601. [DOI] [PubMed] [Google Scholar]
  29. Kelley W. N., Rosenbloom F. M., Seegmiller J. E. The effects of azathioprine (imuran) on purine synthesis in clinical disorders of purine metabolism. J Clin Invest. 1967 Sep;46(9):1518–1529. doi: 10.1172/JCI105643. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Kersley G. D. The pharmaceutical treatment of gout. Ann Phys Med. 1966 May;8(6):199–203. doi: 10.1093/rheumatology/8.6.199. [DOI] [PubMed] [Google Scholar]
  31. Klinenberg J. R., Goldfinger S., Bradley K. H., Seegmiller J. E. An enzymatic spectrophotometric method for the determination of xanthine and hypoxanthine. Clin Chem. 1967 Oct;13(10):834–846. [PubMed] [Google Scholar]
  32. LESCH M., NYHAN W. L. A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION. Am J Med. 1964 Apr;36:561–570. doi: 10.1016/0002-9343(64)90104-4. [DOI] [PubMed] [Google Scholar]
  33. LIDDLE L., SEEGMILLER J. E., LASTER L. The enzymatic spectrophotometric method for determination of uric acid. J Lab Clin Med. 1959 Dec;54:903–913. [PubMed] [Google Scholar]
  34. Maclachlan M. J., Rodnan G. P. Effect of food, fast and alcohol on serum uric acid and acute attacks of gout. Am J Med. 1967 Jan;42(1):38–57. doi: 10.1016/0002-9343(67)90005-8. [DOI] [PubMed] [Google Scholar]
  35. Marks J. F., Baum J., Keele D. K., Kay J. L., MacFarlen A. Lesch-Nyhan syndrome treated from the early neonatal period. Pediatrics. 1968 Aug;42(2):357–359. [PubMed] [Google Scholar]
  36. Melmon K. L., Webster M. E., Goldfinger S. E., Seegmiller J. E. The presence of a kinin in inflammatory synovial effusion from arthritides of varying etiologies. Arthritis Rheum. 1967 Feb;10(1):13–20. doi: 10.1002/art.1780100103. [DOI] [PubMed] [Google Scholar]
  37. Munsat T. L., Klinenberg J., Carell R. E., Menkes J. Defects in purine metabolism and neurologic disease. Bull Los Angeles Neurol Soc. 1968 Apr;33(2):101–112. [PubMed] [Google Scholar]
  38. NIERLICH D. P., MAGASANIK B. REGULATION OF PURINE RIBONUCLEOTIDE SYNTHESIS BY END PRODUCT INHIBITION. THE EFFECT OF ADENINE AND GUANINE RIBONUCLEOTIDES ON THE 5'-PHOSPHORIBOSYL-PYROPHOSPHATE AMIDOTRANSFERASE OF AEROBACTER AEROGENES. J Biol Chem. 1965 Jan;240:358–365. [PubMed] [Google Scholar]
  39. NUGENT C. A., TYLER F. H. The renal excretion of uric acid in patients with gout and in nongouty subjects. J Clin Invest. 1959 Nov;38:1890–1898. doi: 10.1172/JCI103966. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Nishi H. H. Determination of uric acid. An adaptation of the Archibald method on the autoanalyzer. Clin Chem. 1967 Jan;13(1):12–18. [PubMed] [Google Scholar]
  41. PRAETORIUS E., KIRK J. E. Hypouricemia: with evidence for tubular elimination of uric acid. J Lab Clin Med. 1950 Jun;35(6):865–868. [PubMed] [Google Scholar]
  42. Rajan K. T. Lysosomes and gout. Nature. 1966 May 28;210(5039):959–960. doi: 10.1038/210959a0. [DOI] [PubMed] [Google Scholar]
  43. Rosenbloom F. M., Henderson J. F., Caldwell I. C., Kelley W. N., Seegmiller J. E. Biochemical bases of accelerated purine biosynthesis de novo in human fibroblasts lacking hypoxanthine-guanine phosphoribosyltransferase. J Biol Chem. 1968 Mar 25;243(6):1166–1173. [PubMed] [Google Scholar]
  44. Rosenbloom F. M., Kelley W. N., Miller J., Henderson J. F., Seegmiller J. E. Inherited disorder of purine metabolism. Correlation between central nervous system dysfunction and biochemical defects. JAMA. 1967 Oct 16;202(3):175–177. doi: 10.1001/jama.202.3.175. [DOI] [PubMed] [Google Scholar]
  45. SEEGMILLER J. E., GRAYZEL A. I., LASTER L., LIDDLE L. Uric acid production in gout. J Clin Invest. 1961 Jul;40:1304–1314. doi: 10.1172/JCI104360. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. SEEGMILLER J. E., HOWELL R. R. The old and new concepts of acute gouty arthritis. Arthritis Rheum. 1962 Dec;5:616–623. doi: 10.1002/art.1780050610. [DOI] [PubMed] [Google Scholar]
  47. SEEGMILLER J. E., LASTER L., HOWELL R. R. Biochemistry of uric acid and its relation to gout. N Engl J Med. 1963 Mar 28;268:712–contd. doi: 10.1056/NEJM196303282681306. [DOI] [PubMed] [Google Scholar]
  48. SEEGMILLER J. E., LASTER L., STETTEN D., Jr Incorporation of 4-amino-5-imidazolecarboxamide-4-C13 into uric acid in the normal human. J Biol Chem. 1955 Oct;216(2):653–662. [PubMed] [Google Scholar]
  49. Sass J. K., Itabashi H. H., Dexter R. A. Juvenile gout with brain involvement. Arch Neurol. 1965 Dec;13(6):639–655. doi: 10.1001/archneur.1965.00470060075008. [DOI] [PubMed] [Google Scholar]
  50. Seegmiller J. E., Grayzel A. I., Howell R. R., Plato C. THE RENAL EXCRETION OF URIC ACID IN GOUT. J Clin Invest. 1962 May;41(5):1094–1098. doi: 10.1172/JCI104560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  51. Seegmiller J. E., Klinenberg J. R., Miller J., Watts R. W. Suppression of glycine-15N incorporation into urinary uric acid by adenine-8-13C in normal and gouty subjects. J Clin Invest. 1968 May;47(5):1193–1203. doi: 10.1172/JCI105808. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Seegmiller J. E., Rosenbloom F. M., Kelley W. N. Enzyme defect associated with a sex-linked human neurological disorder and excessive purine synthesis. Science. 1967 Mar 31;155(3770):1682–1684. doi: 10.1126/science.155.3770.1682. [DOI] [PubMed] [Google Scholar]
  53. Seegmiller J. E. The acute attack of gouty arthritis. Arthritis Rheum. 1965 Oct;8(5):714–725. doi: 10.1002/art.1780080431. [DOI] [PubMed] [Google Scholar]
  54. Seegmiller J. E. The clinical significance of hyperuricemia. Med Ann Dist Columbia. 1967 Apr;36(4):215–218. [PubMed] [Google Scholar]
  55. Skeith M. D., Simkin P. A., Healey L. A. The renal excretion of indomethacin and its inhibition by probenecid. Clin Pharmacol Ther. 1968 Jan-Feb;9(1):89–93. doi: 10.1002/cpt19689189. [DOI] [PubMed] [Google Scholar]
  56. Sorensen L. B. Suppression of the shunt pathway in primary gout by azathioprine. Proc Natl Acad Sci U S A. 1966 Mar;55(3):571–575. doi: 10.1073/pnas.55.3.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  57. TALBOTT J. H. Gout and blood dyscrasias. Medicine (Baltimore) 1959 May;38(2):173–205. doi: 10.1097/00005792-195905000-00004. [DOI] [PubMed] [Google Scholar]
  58. WYNGAARDEN J. B., ASHTON D. M. The regulation of activity of phosphoribosyl-pyrophosphate amidotransferase by purine ribonacleotides: a potential feedback control of purine biosyntoesis. J Biol Chem. 1959 Jun;234(6):1492–1496. [PubMed] [Google Scholar]
  59. WYNGAARDEN J. B., STETTEN D., Jr Uricolysis in normal man. J Biol Chem. 1953 Jul;203(1):9–21. [PubMed] [Google Scholar]
  60. Wallace S. L. Mechanism of action of colchicine. Arthritis Rheum. 1965 Oct;8(5):744–748. doi: 10.1002/art.1780080435. [DOI] [PubMed] [Google Scholar]
  61. Weissmann G. Lysosomes and joint disease. Arthritis Rheum. 1966 Dec;9(6):834–840. doi: 10.1002/art.1780090611. [DOI] [PubMed] [Google Scholar]
  62. YU T. F., GUTMAN A. B. Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man. J Clin Invest. 1959 Aug;38(8):1298–1315. doi: 10.1172/JCI103905. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Yü T. F., Gutman A. B. Principles of current management of primary gout. Am J Med Sci. 1967 Dec;254(6):893–907. doi: 10.1097/00000441-196712000-00019. [DOI] [PubMed] [Google Scholar]

Articles from California Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES